Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ekso Bionics Holdings (EKSO) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Ekso Bionics Holdings (EKSO) over the last 14 years, with Q3 2025 value amounting to $2.7 million.

  • Ekso Bionics Holdings' Cash & Equivalents fell 6717.32% to $2.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.7 million, marking a year-over-year decrease of 6717.32%. This contributed to the annual value of $4.5 million for FY2024, which is 4798.56% down from last year.
  • According to the latest figures from Q3 2025, Ekso Bionics Holdings' Cash & Equivalents is $2.7 million, which was down 6717.32% from $5.2 million recorded in Q2 2025.
  • Ekso Bionics Holdings' 5-year Cash & Equivalents high stood at $49.5 million for Q1 2021, and its period low was $2.7 million during Q3 2025.
  • In the last 5 years, Ekso Bionics Holdings' Cash & Equivalents had a median value of $13.3 million in 2023 and averaged $20.5 million.
  • Per our database at Business Quant, Ekso Bionics Holdings' Cash & Equivalents surged by 48171.68% in 2021 and then crashed by 6717.32% in 2025.
  • Over the past 5 years, Ekso Bionics Holdings' Cash & Equivalents (Quarter) stood at $40.4 million in 2021, then tumbled by 49.2% to $20.5 million in 2022, then plummeted by 57.91% to $8.6 million in 2023, then plummeted by 47.99% to $4.5 million in 2024, then crashed by 39.42% to $2.7 million in 2025.
  • Its Cash & Equivalents stands at $2.7 million for Q3 2025, versus $5.2 million for Q2 2025 and $8.1 million for Q1 2025.